Even though Novartis grew sales and profits in the last quarter of 2023, the magnitude of the increases was not satisfactory to the Swiss pharma's investors.
Novartis’ fourth-quarter sales grew 10% year over year at constant currencies to $11.4 billion. The number missed analysts’ expectations by 1%, according to the team at ODDO BHF. The company’s stock price fell 3% Wednesday morning as of publication.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,